Prospective comparison of low-fluence photodynamic therapy combined with intravitreal bevacizumab versus bevacizumab monotherapy for choroidal neovascularization in age-related macular degeneration

Seminars in Ophthalmology

Volumn 30, Issue 2, 2015, Pages 112-117

  Datseris, Ioannis ^a   Kontadakis, Georgios A ^b   Diamanti, Ramza ^a   Datseris, Iordanis ^a   Pallikaris, Ioannis G ^b   Theodossiadis, Panagiotis ^c   Tsilimbaris, Miltiadis K ^b  

^a Institute of Ophthalmology   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Age related macular degeneration; Bevacizumab; Choroidal neovascularization; Photodynamic therapy; Verteporfin

Indexed keywords

BEVACIZUMAB; VERTEPORFIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; PHOTOSENSITIZING AGENT; PORPHYRIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CENTRAL MACULAR THICKNESS; CENTRAL RETINAL THICKNESS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REDUCED FLUENCE PHOTODYNAMIC THERAPY; RETINA FOVEA; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY; PHYSIOLOGY; PROCEDURES; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84924034046     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2013.833268     Document Type: Article

References (27)

1. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988;32:375-413.
2. Schmidt-Erfurth UM, Pruente C. Management of neovas-cular age-related macular degeneration. Prog Retin Eye Res 2007;26:437-451.
3. Bressler SB. Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology 2009;116:S1-S7.
4. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-870.
5. Klein RM, Klein RB. Avastin versus Lucentis: Ethical issues in treatment of age-related macular degeneration. Retina 2007;27:1163-1165.
6. Ladas ID, Karagiannis DA, Rouvas AA, et al. Safety of repeat intravitreal injections of bevacizumab versus rani-bizumab: Our experience after 2, 000 injections. Retina 2009; 29:313-318.
7. Lyall DA, Tey A, Foot B, et al. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: Incidence, features, risk factors, and outcomes. Eye (Lond) 2012;26: 1517-1526.
8. Stewart MW. Endophthalmitis after injections of anti-vascular endothelial growth factor drugs. Retina 2011;31: 1981-1982.
9. Inoue M, Kobayakawa S, Sotozono C, et al. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor. Ophthalmologica 2011;226:145-150.
10. Moshfeghi AA, Rosenfeld PJ, Flynn Jr HW, et al. Endophthalmitis after intravitreal anti-vascular endothelial growth antagonists. Retina 2011;31:662-668.
11. Kaiser PK, Boyer DS, Cruess AF, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month results of the DENALI study. Ophthalmology 2012;119:1001-1010.
12. Sivaprasad S, Patra S, DaCosta J, et al. A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexametha-sone and oral minocycline for neovascular age-related macular degeneration. Ophthalmologica 2011;225:200-206.
13. Singh CN, Saperstein DA. Combination treatment with reduced-fluence photodynamic therapy and intravitreal injection of triamcinolone for subfoveal choroidal neovas-cularization in macular degeneration. Retina 2008;28: 789-793.
14. Smith BT, Dhalla MS, Shah GK, et al. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Retina 2008;28:675-681.
15. Treatment of age-related macular degeneration with photo-dynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age related macular degeneration with verteporfin: one year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol 1999;117:1329-1345.
16. Blinder KJ, Bradley S, Bressler NM, et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1 Am J Ophthalmol 2003;136:407-418.
17. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macu-lar degeneration. Ophthalmology 2006;113:363-372.
18. Carneiro AM, Barthelmes D, Falcao MS, et al. Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmologica 2011;225: 211-221.
19. Dhalla MS, Shah GK, Blinder KJ, et al. Combined photo-dynamic therapy with verteporfin and intravitreal bevaci-zumab for choroidal neovascularization in age-related macular degeneration. Retina 2006;26:988-993.
20. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizu-mab (Avastin) in combination with verteporfin photo-dynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IbeVe Study). Graefes Arch Clin Exp Ophthalmol 2007;245: 1273-1280.
21. Ladewig MS, Karl SE, Hamelmann V, et al. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2008;246:17-25.
22. Ahmadieh H, Taei R, Soheilian M, et al. Single-session photodynamic therapy combined with intravitreal bevaci-zumab for neovascular age-related macular degeneration. Eur J Ophthalmol 2008;18:297-300.
23. Boyer DS, Garcia R, Hao Y, et al; Registry of Visudyne AMD Therapy Writing Committee. Verteporfin photo-dynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2009;116:747-755.
24. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascu-larization due to age-related macular degeneration. Ophthalmology 2007;114:1179-1185.
25. Costagliola C, Romano MR, Rinaldi M, et al. Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Br J Ophthalmol 2010;94:180-184.
26. Schmidt-Erfurth U, Schlötzer-Schrehard U, Cursiefen C, et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003;44:4473-4480.
27. Schmidt-Erfurth U, Laqua H, Schlötzer-Schrehard U, et al. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 2002;120:835-844.